Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
Unimolecular dual agonist. It does not include a glucagon-receptor agonist domain.
Forums that call every incretin "GLP-1" erase the GIP half of this molecule.
GIP and GLP-1 receptors on the pancreas and brain are the intended targets. Gastric emptying slows. Hypoglycemia becomes more plausible when a sulfonylurea or insulin is already forcing insulin release.
There is no glucagon-receptor agonist activity in this molecule. Forum comparisons that treat it as retatrutide miss that pathway.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Dual-agonist stacks · unverified
Forums compare tirzepatide with semaglutide and retatrutide as if milligrams were interchangeable, and they add repair peptides on top. The receptor sets differ. The posts do not correct that.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.